Intraductal Papillary Mucinous Neoplasms of the Pancreas: Challenges and New Insights by Zambudio Carroll, Natalia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Intraductal Papillary Mucinous Neoplasms of the
Pancreas: Challenges and New Insights
Natalia Zambudio Carroll, Betsabé Reyes and
Laureano Vázquez
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/66491
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Natalia Zambudio Carroll, Betsabé Reyes 
and Laureano Vázquez
Additional information is available at the end of the chapter
Abstract
Cystic lesions of the pancreas are a common entity with almost a 25% incidence of the 
general population. These types of lesions are being increasingly diagnosed partly 
explained due to the technological advances over the past years. The management and 
treatment varies per cyst type. However, the most threatening cyst lesions are intraductal 
papillary mucinous neoplasms (IPMNs). These lesions represent nowadays a relatively 
new clinical entity and in many aspects remain poorly understood. The aim of this 
­chapter­is­to­provide­a­comprehensive­review­of­the­classification,­diagnosis,­treatment­
and follow-up strategy.
Keywords:­IPMN,­BD-IPMN,­BD-IPMN,­classification,­malignancy­risk,­pathogenesis,­
management, surveillance
1. Introduction
In the face of this new “epidemic of pancreatic cysts,” it is clear that we need to be on top of 
newly emerging changes in our current daily practice. Pancreatic cancer has a fateful prog-
nosis, despite recent improvements in surgery and chemotherapy. However, most cases of 
intraductal papillary mucinous neoplasms (IPMNs) are considered as premalignant lesions, 
thus­making­them­a­target­for­diagnosis­and­prompt­treatment.­On­the­other­hand,­we­should­
never­forget­the­short-­and­long-term­risks­of­surgery.­This­is­precisely­why­it­is­so­challeng-
ing to adequately manage this pathology.
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Biomarkers­ represent­ an­ interesting­ opportunity,­ but­ until­ they­ can­ be­ used­ on­ a­ regular­
­clinical­ basis,­ we­ are­ obliged­ to­ say­ knowledgeable­ on­ new­ insights­ involving­ radiologic­
 characteristics and potential malignancy prior to deciding, which is the best available indi-
vidualized option for each patient.
2. Classification
2.1. Anatomic classification: involvement of the pancreatic ductal system
Most IPMN arise from the pancreatic main duct or its branch ducts (Figure 1). Most of 
these­tumors­are­unifocal,­20–30%­are­multifocal,­and­5–10%­of­the­IPMN­diffusely­affect­
the entire duct system of the pancreas. Depending on the involvement of the pancreatic 
duct,­ IPMNs­are­ classified­as­either­main­duct­ IPMN­(MD-IPMN)­or­branch­duct­ IPMN­
(BD-IPMN).­ If­ both,­main­ and­ branch­ ducts­ are­ involved­ together,­ then­ it­ is­ defined­ as­
combined-type IPMN (Figure 2). The clinical pathologic behavior of combined-type IPMN 
is similar to that of MD-IPMN. MD-IPMN is frequently more associated with this malig-
nant transformation than is BD-IPMN, requiring surgical resection in more than a half of 
the patients, while most patients with BD-IPMN can be observed for a long time after the 
diagnosis.
Figure 1. Types­of­IPMN:­MD-IPMN,­BD-IPMN,­mixed­type-IPMN.­Modified­from:­Bliss­D­(Illustrator)­2001.­Pancreas,­
Duodenum,­and­Small­Intestine­[image].­Available­at:­https://visualsonline.cancer.gov/details.cfm?imageid=4364.
Figure 2. Differences­between­MD-IPMN­and­BD-IPMN.
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2.2. Histologic classification: IPMN subtype
Immunohistochemical­staining­with­mucin­antibodies­enables­differentiation­between­tumors­
with­different­prognoses.­Four­subtypes­of­IPMNs­have­been­characterized:­gastric,­intestinal,­
pancreatobiliary, and oncocytic. Most of BD-IPMNs are composed of gastric-type epithelium. 
However, intestinal type is more common in MD-IPMN. In a recent report, the four subtypes 
of­IPMNs­were­associated­with­significant­differences­in­survival.­Patients­with­gastric-type­
IPMN had the best prognosis, whereas those with intestinal and pancreatobiliary type had a 
bad prognosis [1–6].
2.3. World Health Organization (WHO)
The­World­Health­Organization­(WHO)­classified­IPMNs­into­three­subgroups­according­to­
degree of dysplasia: (I) IPMN with low- or intermediate-grade dysplasia; (II) IPMN with high-
grade dysplasia (carcinoma in situ); and (III) IPMN with an associated invasive carcinoma. 
IPMN associated with PDAC (pancreatic ductal adenocarcinoma arising in association with 
an­ IPMN)­was­ further­classified­ into­ two­subtypes:­ tubular­adenocarcinoma,­composed­of­
predominantly­gland-forming­neoplastic­cells­with­fibrotic­stroma­and­absence­of­­significant­
extracellular stromal mucin and colloid carcinoma (mucinous noncystic  carcinoma), 
 composed of sparsely populated strips, clusters, or individual neoplastic cells residing within 
extensive pools of extracellular mucin [6]. In case of IPMN with low- to intermediate-grade 
of dysplasia, dysplastic changes in the columnar cells are minimal or absent. The prognosis 
is usually favorable [7].
3. Malignancy risk
There has been an increased prevalence of pancreatic cystic neoplasms, frequently being found 
in elderly asymptomatic patients. This is partially caused by the greater number of cross-sec-
tional studies being performed. Though images obtained through the use of computed tomog-
raphy (CT-scan) and magnetic resonance imaging (MRI), we are able to estimate the prevalence 
of­pancreatic­cysts­in­2.5%­of­the­population.­This­figure­increases­over­time;­around­the­age­of­
70 years or older, 10% of the population has pancreatic cysts and 20–50% of them are IPMN [8].
The­real­risk­of­malignancy­may­be­very­low,­but­the­diagnosis­is­associated­with­anxiety­
and­usually­leads­to­further­medical­testing­in­order­to­confirm­malignancy.­The­most­fre-
quently­used­tests­are­likely­to­include:­consultations­con­gastroenterologists­and/or­oncolo-
gists, endoscopic ultrasound with or without percutaneous biopsy, and occasionally surgery 
[6, 8, 9]. This is one of the reasons why more and more studies are focusing on evaluating 
the malignancy rate for pancreatic cancer distinct from IPMN and also for pancreatic cancer 
arising­from­IPMN.­Figures­are­rather­variable,­but­over­the­course­of­several­years,­we­have­
been able to see how the rates for malignancy, especially in SB-IPMN, are found to be lower.
Not­ only­ IMPNs­ are­ associated­ with­ pancreatic­ malignancies­ but­ also­ it­ is­ known­ that­
 extrapancreatic malignancies are more frequently found in these patients.
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3.1. Pancreatic malignancies
3.1.1. Pancreatic cancer arising from IPMN
3.1.1.1. MD-IPMN
The­malignancy­risk­in­this­type­of­situation­is­very­clear­which­makes­the­decision­to­perform­
surgery­also­much­easier.­Many­studies­have­estimated­the­overall­risk­ranges­between­36­and­
92% [10–13].­Overall,­the­prognosis­after­resection­is­generally­favorable­as­long­as­its­inva-
sion remains within minimally invasive or in T1a status (depth of stromal invasion <5 mm).
3.1.1.2. BD-IPMN
In­this­case,­there­are­more­controversial­figures.­Estimated­rates­here­can­range­from­6­to­47%­
[8, 11–13]. In 2013, Gardner et al. [8]­lower­the­current­25%­lifetime­risk­of­malignant­transfor-
mation and presented the prevalence of mucin-producing adenocarcinoma in patients diag-
nosed with pancreatic cysts to be 33.2 per 100,000 patients. A linear increment was detected 
when­studying­male­patients­between­the­ages­of­80–84.­In­that­group,­the­prevalence­was­
38.6­per­100,000­patients.­Only­one­systematic­review­by­Crippa­et­al.­[14] is considered to be 
the­first­meta-analyses­focused­in­the­risk­of­developing­pancreatic­malignancies,­including­
malignant­BD-IPMNs­and­PDAC,­as­well­as­the­risk­of­death­due­to­pancreatic­malignancy­
in patients undergoing nonoperative management for BD-IPMNs. The estimated overall 
 pancreatic malignancy rate is 3.7%, an incidence of malignancy in 7 cases per 1000 per years 
and­an­annual­risk­on­only­0.7%.­This­is­the­rate­that­is­entirely­comparable­with­the­90-day­
postoperative mortality rate following pancreatic resections found at many high-volume 
­centers.­Thus,­choosing­surgery­in­these­cases­does­not­justify­for­avoiding­the­unlikely­pro-
gression­from­“low-risk”­BD-IPMN­to­invasive­tumors.
3.1.2. Pancreatic cancer distinct from IPMN
There­appears­to­be­a­“field­defect,”­which­may­give­rise­to­both­IPMN­and­pancreatic­duct­
adenocarcinoma (frequently related to gastric subtype) occurring in 2–5% of patients diag-
nosed with IPMN [6, 10]. Also, Crippa et al. [14] lower the previous rates with an estimate of 
incidence­of­only­2­cases­per­1000­per­year­and­an­annual­risk­of­0.2%.
3.2. Extrapancreatic malignancies
Colorectal, gastric, bile duct, renal cell, and thyroid cancers are relatively frequently associ-
ated with IPMNs [15–17].
4. Pathogenesis
IPMNs are mucinous cystic lesions of the pancreas that are characterized by neoplastic, 
mucin-secreting, and papillary cells projecting from the pancreatic ductal surface. They arise 
from the epithelial lining of the main pancreatic duct or its side branches. Intraductal prolif-
eration of mucin-producing columnar cells is the main histologic characteristic of IPMNs, and 
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intraluminal growth causes dilatation of the involved duct and its proximal segment. They 
are usually found in the head of the pancreas as a solitary cystic lesion, but in 20–30% of the 
cases,­they­may­be­multifocal,­and­in­5–10%­of­cases,­they­may­involve­the­pancreas­diffusely­
[18–20].­In­BD-IPMN,­malignant­tumors­can­be­found­in­6–46%­and­in­MD-IPMN­in­57–92%,­
making­that­MD-IPMN­leads­to­worse­prognosis­[5].
4.1. Progression to pancreatic cancer
IPMNs are thought to follow an orderly progression from a benign neoplasm to invasive 
carcinoma of the pancreas, they range from premalignant lesions with low-grade dysplasia to 
invasive malignancy, and they have a clear tendency to become invasive carcinoma [5, 21–24]. 
It­has­been­estimated­a­5–6­year­progression­rate,­depending­on­the­subtype.­They­are­graded­
according to the most atypical area in the lesion as:
• Low-grade dysplasia (adenoma).
• Moderate dysplasia (borderline).
• High-grade dysplasia (carcinoma in situ).
• Invasive carcinoma.
5. Clinical presentation
5.1. Risk factors
It has been described that previous history of diabetes, especially with insulin dependency, 
chronic pancreatitis, or a familial history of pancreatic ductal adenocarcinoma (PDAC), may 
have­a­higher­risk­for­IPMN­[25]. Also, several studies have noticed that the presence of auto-
immune disease in general population is around 5%; however, in patients diagnosed with 
IPMN, the number rises up to 22%. IPMNs can be associated with systemic diseases such as: 
systemic­lupus­erythematous­and­rheumatoid­arthritis­an­inflammatory­bowel­disease,­lead-
ing­to­think­that­IMPNs­may­be­one­manifestation­of­a­more­systemic­disease­[26].
5.2. Symptoms
Most­IPMNs­are­diagnosed­between­60­and­70­years­of­age.­There­is­a­slightly­higher­prevalence­
in men than women [7].­Some­patients­present­symptoms­at­ the­time­of­diagnosis­(7–43%),­
being more frequent the presence of abdominal pain, jaundice, and previous history of pancre-
atitis.­Other­symptoms­are­as­follows:­weight­loss,­nausea­or­vomiting,­and­diabetes­[5, 6, 27].
6. Evaluation for malignancy
Several tests can be performed when confronted with a possible IPMN. Regarding this sub-
ject,­some­changes­have­occurred­recently,­most­of­them­centering­on­the­use­of­EUS-FNA­
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(endoscopic­ultrasonography/fine-needle­aspiration)­and­endoscopic­ retrograde­cholangio-
pancreatography­(ERCP)­and­analyses­of­the­obtained­fluid­(Figure 3).
6.1. Cross-sectional imaging
Magnetic resonance cholangiopancreatography (MRCP) and computerized axial tomography 
scan­(CAT­scan)­are­useful­as­the­first­step,­and­perhaps­the­only­one,­if­results­are­very­clear­
(see management) (Figure 4). It is useful to describe:
• Anatomical characteristics: lymph node involvement and main pancreatic duct 
involvement.
• Mural nodules: IPMN with >3 mm nodules is highly suggestive of malignancy.
Figure 3. General sequence when diagnosing IPMNs.
Figure 4. MRCP images of MD-IPMN (left) and BD-IPMN (right).
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6.2. EUS-FNA
This technique has been evolving, and more hospitals are incorporating it into their routine 
diagnostic tests, helping to introduce its more general application and obtaining information by:
• Describing sonographic characteristics: mural nodes and invasion.
• Performing­pancreatic­and­cyst­fluid­analysis:­cellularity,­CEA­determination­and­molecu-
lar­markers­KRAS­with­or­without­GNAS­mutation,­TP53,­PIK3CA,­p16/CDKN21,­SMAD4,­
or­PTEN­mutation­(28).
On­the­2012­international­consensus­guidelines­[28], certain recommendations were made as 
to­when­to­use­EUS-FNA:
• Pancreatic cysts with worrisome features.
• Pancreatic small cyst with worrisome features.
• >3­cm­cysts­with­no­worrisome­features,­especially­if­elderly­patients­to­verify­the­findings.
• Distinction­of­BD-IPMN­versus­serous­cyst­neoplasm­(SCN)­with­CEA­determination.
Nonetheless, the more recent American Gastroenterological Association (AGA) guideline on 
the management of pancreatic cysts [29] issues a conditional recommendation: “pancreatic 
cysts­with­at­least­two­high-risk­features,­such­as­size­≥3­cm,­a­dilated­main­pancreatic­duct,­
or the presence of an associated solid component, should be examined with endoscopic ultra-
sonography­with­fine-needle­aspiration­(EUS-FNA)”­(Figure 5).
Macroscopically,­ highly­ viscous­ fluid­ is­ the­ first­ clue­ that­ the­ cyst­ is­ mucinous­ cyst.­
Furthermore,­ high­ concentration­ of­ CEA­ reflects­ the­ presence­ of­ a­ mucinous­ epithelium,­
and­it­is­elevated­in­both­IPMNs­and­MCNs.­Thus,­it­is­quite­beneficial­to­distinguish­muci-
nous­cysts­from­non-mucinous.­A­cut-off­CEA­level­of­192­ng/mL­has­the­sensitivity­of­73%,­
specificity­of­84%.­Due­to­connectivity­to­the­pancreatic­ductal­system,­amylase­level­may­be­
elevated in IPMNs.
In­conclusion,­the­most­recent­papers­encourage­the­use­of­EUS-FNA­in­the­initial­diagnostic­
tests [15, 30] to identify smaller cysts with high grade or invasive pathology [30] and to detect 
mural nodules otherwise missed on cross-sectional imaging or malignant cytology in lesions 
>3­ cm.­The­high­ specificity­ and­ accuracy­of­EUS­ strongly­position­ it­ as­ the­ optimum­ tool­
for diagnosing malignant BD-IPMNs, particularly in patients without worrisome features 
and with smaller cysts [31].­It­is­particularly­important­to­consider­that­inherent­risks­can­be­
derived from this test, including complications associated with these endoscopic procedures 
such­as­difficulty­in­cytological­interpretation­of­samples­and­relatively­low­sensitivity­[31].
6.2.1. Biomarkers
DNA­analysis­of­pancreatic­ cyst­fluid­demonstrated­ that­KRAS­mutation­ is­highly­ spe-
cific­ (96%)­ for­mucinous­ cysts,­ but­ the­ sensitivity­ is­ only­ 45%.­KRAS­ is­ an­ early­ onco-
genic mutation in the adenoma-carcinoma sequence but cannot discriminate a benign from 
malignant mucinous cyst. A recent study [32] demonstrated that the “GNAS mutation 
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detected­ in­cyst­fluid­can­separate­ IPMN­from­MCN,­but­similar­ to­KRAS­mutations,­ it­
does not predict malignancy. The absence of a GNAS mutation also does not correlate with 
a diagnosis of MCN because not all IPMNs will demonstrate a GNAS mutation [33–35]. 
A­GNAS­mutation­was­present­in­66%­of­IPMNs.”­But­a­recent­mutations­study­in­GNAS­
at­codon­201­has­been­identified­in­duodenal­fluid­samples­even­before­the­IPMN­lesion,­
which­was­identified­on­radiologic­imaging­[36]. Moreover, one study reports that 33% of 
incipient IPMNs analyzed have a GNAS mutation, suggesting that a large proportion of 
incipient IPMNs are part of the IPMN pathway, and these mutations occur early in this 
process [6, 37].
A­ recent­ study­ identified­ glucose­ and­ kynurenine­ to­ be­ differentially­ expressed­ between­
non-mucinous and mucinous pancreatic cysts [38]. Metabolic abundances for both were sig-
nificantly­lower­in­mucinous­cysts­compared­with­non-mucinous­cysts.­The­clinical­utility­of­
Figure 5. Use­of­EUS-FNA­according­to­2012­International­Consensus­Guidelines­[28] and AGA Guidelines [29].
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these­biomarkers­will­be­addressed­in­future­studies­although­it­is­clear­that­it­will­be­of­great­
utility­when­differentiating­benign­vs.­malignant­cysts.
6.3. Other procedures
6.3.1. ERCP
For­sampling­of­fluid­brushes­in­the­2012­International­Consensus­Guidelines­for­the­manage-
ment­of­IPMN,­routine­use­of­this­test­was­not­recommended­and­was­left­only­for­scientific­
purposes [28]. However, as professionals are becoming more familiarized with it and results 
are increasingly being more accurate, newer studies are encouraging cytology of the pan-
creatic juice and it is starting to be considered a reliable predictor of malignancy in IPMN 
[39]. Cytological examination alone is often non-diagnostic due to the low cellularity of the 
aspirated­fluid.­A­positive­or­negative­diagnosis­can­be­obtained­through­a­cytology­analyses­
with­a­100%­specificity.­Moreover,­if­a­high-grade­epithelial­atypia­is­found­in­the­cyst­fluid,­
it is correlated with an 80% chance of malignancy [40].
6.3.2. PET scan
Positron emission tomography has been proposed as a useful technique for diagnosing and 
staging­ different­ malignancies.­ Several­ studies­ have­ investigated­ the­ outcomes­ in­ IPMN­
cases,­ concluding­ that­dual-phase­F-18­fluorodeoxyglucose­positron­ emission­ tomography­
with­computed­tomography­(FDG-PET/CT)­has­an­overall­specificity­of­92–95%­and­a­sensi-
tivity­of­88–94%­when­trying­to­differentiate­malignant­IPMNs­vs.­benign­lesions.­It­has­been­
proposed­that­PET­scans­should­be­performed­in­older­patients,­cases­at­increased­surgical­
risk,­or­when­the­feasibility­of­parenchyma-sparing­surgery­demands­a­reliable­preoperative­
exclusion of malignancy [41, 42].
7. Management
To date, three consensus guidelines have been proposed to manage pancreatic cystic 
lesions­beginning­with­the­original­2006­Sendai­guideline,­which­was­revised­in­2012­by­the­
International­Association­of­Pancreatology­(IAP)­in­Fukuoka,­and­the­recent­AGA­guideline­
[43–45].
All­guides­agree­that­due­to­the­higher­risk­of­malignancy,­all­symptomatic­cysts­should­be­
further evaluated or resected, depending on the clinical circumstances.
Invasive carcinoma in patients with asymptomatic cysts is very rare, especially in cysts 
<10­mm.­ In­ such­ cases,­ no­ further­work-up­will­ be­ needed;­ however,­ follow-up­ is­ still­
recommended [43–46].­For­better­characterization­of­the­lesions,­pancreatic­protocol­CT­or­
gadolinium-enhanced MRI with magnetic resonance cholangiopancreatography (MRCP) 
is recommended for cysts >10 mm [47]. The most recent consensus among radiologists [10] 
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suggests that MRI is preferable for evaluating cysts due to its high-contrast resolution, the 
identification­of­septum,­nodules,­and­duct­communications.­Also,­MRI­is­the­preferable­
follow-up test because it avoids excessive exposure to radiation [47].
According to Fukuoka guidelines (1), there are:
• “Worrisome features”:
 – Cyst­of­≤3­cm.
 – Thickened­enhanced­cyst­walls.
 – MPD of 5–9 mm.
 – Non-enhanced mural nodules.
 – Abrupt change in the MPD caliber with distal pancreatic atrophy.
 – Lymphadenopathy.
• “High-risk stigmata”:
 – Obstructive­jaundice­in­a­patient­with­a­cystic­lesion­of­the­pancreatic­head.
 – Enhanced­solid­component,­MPD­size­of­10­mm.
All patients with cysts of 3 cm in size without “worrisome features” should undergo sur-
veillance­according­ the­size­stratification.­Patients­with­cysts­of­>3­cm­and­no­“worrisome­
features”­can­also­be­considered­for­EUS­to­verify­the­absence­of­thickened­walls­or­mural­
nodules, particularly if the patient is elderly. All smaller cysts with “worrisome features” 
should­be­evaluated­by­EUS­to­further­risk­stratify­the­lesion­[48].
7.1. Surgery
If surgery is considered for a pancreatic cyst, patients are referred to a center with demon-
strated expertise in pancreatic surgery. Surgery is the only treatment option in patients with 
IPMN of the pancreas with high-grade dysplasia or IPMNs that have progressed to invasive 
carcinoma (Figure 6).
7.1.1. Indications
 - High-grade dysplasia or Invasive carcinoma.
 - High-risk­stigmata­+­positive­cytology.
 - High-risk­stigmata­confirmed­by­MRI­and­EUS.
 - Symptomatic cyst.
 - Younger­patients­with­cyst­>2­cm­owing­to­cumulative­risk.
Positive­cytology­on­EUS-guided­FNA­has­the­highest­specificity­for­diagnosing­malignancy.­
If­there­is­a­combination­of­high-risk­features­on­imaging,­then­this­is­likely­to­increase­the­
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Figure 6. Proposed algorithm for surgery indications in IPMNs.
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risk­of­malignancy.­Even­in­the­face­of­a­negative­cytology,­if­EUS­and­MRI­confirm­high-risk­
stigmata,­the­specificity­is­likely­to­be­high.­However,­no­currently­available­data­can­demon-
strate­the­impact­of­multiple­high-risk­features.­Molecular­techniques­to­evaluate­pancreatic­
cysts remain an emerging area of research [23, 49, 50],­but­had­the­benefits­of­surgery­out-
weigh­the­risks­in­this­selected­population­[51].
The most important aspect of resection is to achieve complete removal of a tumor with a nega-
tive margin. If a positive margin is found in a high-grade dysplasia, additional resection of the 
pancreas should be performed. However, there is no consensus regarding further resection in 
the case of a low- or moderate-grade dysplasia [51, 52].
Total pancreatectomy should be contemplated only in younger patients who can manage 
the­comorbidities­related­to­diabetes­and­exocrine­insufficiency­or­in­patients­with­a­history­
of diabetes [53, 54]. The choice of surgery will be determined by the location of the tumor 
and the extent of involvement of the gland. It is not clearly established that multifocality 
corresponds­to­a­higher­risk­of­invasive­cancer;­in­most­cases­with­more­than­one­lesion,­the­
dominant or concerning lesions are resected; and the others are observed with follow-up 
imaging [1].
Regarding the BD-IPMN that occurs in elderly patients, the annual malignancy rate is only 
2–3%. These factors support a conservative management with follow-up in patients who do 
not­have­ risk­ factors­predicting­malignancy.­Younger­patients­ (<65­years)­with­ a­ cyst­ size­
of­>2­cm­may­be­candidates­for­resection­owing­to­the­cumulative­risk­of­malignancy­[27]. 
BD-IPMN of >3 cm without these signs can be observed without immediate resection, particu-
larly in elderly patients. The decision needs to be individualized and to depend not only on 
the­risk­of­malignancy­but­also­on­the­patient’s­conditions­and­cyst­location­[51].
7.2. Adjuvant therapy
It­ has­ not­ yet­ been­ determined­whether­ or­ not­ to­ offer­ postresection­ adjuvant­ therapy­ to­
patients­with­IPMNs­that­have­progressed­to­invasive­carcinoma;­it­also­undefined­as­to­the­
optimal strategy for postoperative therapy (chemoradiotherapy versus chemotherapy alone) 
remains­undefined­[55]. A recent study by McMillan et al. [56] suggests that patients classi-
fied­as­AJCC­stage­II­ through­IV,­presenting­with­positive­lymph­nodes,­positive­resection­
margins­or­poorly­differentiated­tumors,­may­benefit­from­adjuvant­chemoradiotherapy­over­
chemotherapy­alone­in­terms­of­overall­survival,­except­for­patients­who­had­AJCC­patho-
logic stage II disease.
8. Follow-up
The­AGA­recommends­discussing­the­risks­and­benefits­of­a­management­strategy­with­the­
patient as a good clinical practice for nearly all diseases and interventions. Patients need to 
receive a full explanation of all therapeutical options so they can choose the best treatment in 
accordance with the most recent guidelines. Patients who have a limited life expectancy do 
not­derive­any­benefit­from­surveillance,­because­it­is­inappropriate­for­patients­who­are­not­
surgical candidates due to severe comorbidities.
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The­ Fukuoka­ consensus­ has­ high­ sensitivity­ of­ the­ diagnosis­ of­ IPMN­ and­ prediction­ of­
malignancy [57],­although­the­cyst­size­from­the­“high-risk­stigmata”­to­“worrisome­features”­
is­still­a­matter­of­controversy­[57–60]. A systematic review of the literature suggests that size 
>3­cm­increased­the­risk­of­malignancy­by­approximately­3­times­and­the­presence­of­a­solid­
component­increased­the­risk­of­malignancy­approximately­eight­times­[58].
8.1. MD-IPMN
The­management­depends­on­the­degree­of­ductal­dilation,­≥10­mm,­if­the­duct­is­(Figure 7)
 - ≥10 mm in diameter: resection of MD-IPMN is recommended for patients who have 
good performance status with reasonable life expectancy. This recommendation is based 
on the high rate of malignancy in MD-IPMN [28].
 - 5–9 mm:­we­need­additional­evaluation­with­EUS­and­fine-needle­aspiration.­Surgery­is­
then indicated if there is evidence of worrisome features. But the association of malig-
Figure 7. Follow-up­for­MD-IPMN­<10­mm.
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nancy with this degree of pancreatic duct dilation has not been well characterized. If the 
patient­has­a­longer­life­expectancy,­up­to­10­years,­he­should­be­operated.­For­patients­
not undergoing surgery, we perform a magnetic retrograde cholangiopancreatography 
(MRCP) a year later. Surgery should be considered if the duct increases in size or if intra-
mural nodules develop. If the duct is stable, we should repeat imaging every 2 years and 
continue it as long as the patient is a good surgical candidate.
 - <5 mm: follow-up with MRCP in 2 years. As with other IPMNs, surgery is indicated if 
the duct increases in size or if intramural nodules develop. If the duct is stable on repeat 
imaging, we lengthen the surveillance interval to every 2–3 years and continue surveil-
lance as long as the patient remains a good surgical candidate.
8.2. BD-IPMN
Resection­is­generally­indicated­if­there­are­high-risk­stigmata­and­if­patient­has­symptoms­
attributable­ to­ the­ IPMN.­ Besides,­ surgery­ is­ indicated­ if­ there­ is­ evidence­ of­ worrisome­
­features­or­positive­cytology.­We­must­always­take­into­account­the­patient’s­age,­life­expec-
tancy, and performance status [28] (Figure 8)
• ≥30 mm: repeat MRCP in 1 year. If the IPMN is stable, continue surveillance with MRCP 
every 2 years.
• 10–30 mm: repeat MRCP in 1 year. If the IPMN is stable, continue surveillance with MRCP 
every 2 years. After 5 years, the surveillance interval can be lengthened to every 3 years.
• <10 mm: repeat in 1 year. If the IPMN is stable, continue surveillance with MRCP every 2 
years. After 5 years, surveillance can be discontinued.
Follow-up­is­made­if­the­patient­is­a­good­surgical­candidate.­If,­during­surveillance,­there­are­
changes­in­the­IPMN,­a­EUS-FNA­should­be­performed.
MRI is the preferred surveillance imaging modality over computed tomography. The length 
of surveillance for IPMN is another concern for every clinician. If there is no change in size 
or characteristics, the AGA suggests that patients without worrisome pancreatic features 
undergo MRI for surveillance in 1 year and then every 2 years after, for a total of 5 years. The 
review­of­the­literature­suggests­that­the­risk­of­malignant­transformation­of­pancreatic­cysts­
is­approximately­0.24%­per­year.­The­risk­of­cancer­in­cysts­without­a­significant­change­over­
a 5-year period is lower but this recommendation has very low evidence quality. Therefore, 
more studies are needed [45].­ In­ addition,­ the­ Fukuoka­ consensus­ suggests­ for­ BD-IPMN­
follow-up:­yearly­follow-up­if­lesion­is­<10­mm­in­size,­6–12­monthly­follow-up­for­lesions­
between­10­and­20­mm,­and­3–6­monthly­ follow-up­ for­ lesions­>20­mm­[28]. The optimal 
surveillance approach, however, remains unclear.
8.3. Combined main duct and branch duct IPMN
Each­lesion­is­managed,­as­it­would­be­if­it­were­the­only­lesion.
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8.3.1. Surveillance following surgery
• Noninvasive­ IPMN:­ the­risk­of­developing­a­ recurrence­ in­ the­remaining­pancreas­ is­at­
least 5%. So we have to perform the follow-up with MRCP by including a lengthening in 
Figure 8. Follow-up­algorithm­for­BD-IPMN.
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the surveillance interval if no changes are detected after several years. If there is another 
nonresected IPMN, follow-up should continue as stated above [23, 61].
• Invasive­carcinoma:­ studies­ say­ that­ the­ risk­of­ IPMN­recurrence­ is­25–50%­[62], and it 
recommended­surveillance­every­6­months­[28]. If we diagnose patients, a recurrence of 
IPMN­will­need­EUS­for­evaluation.
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